Treatment of Helicobacter pylori infection

Minerva Gastroenterologica e Dietologica

Volumn 49, Issue 1, 2003, Pages 1-9

  Fallone, C A ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Dyspepsia; Gastroesophageal reflux, diagnosis; Helicobacter infections, drug therapy; Stomach, neoplasms.

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TETRACYCLINE DERIVATIVE;

ALLERGY; ANTIBIOTIC RESISTANCE; ATROPHIC GASTRITIS; CARCINOGENIC ACTIVITY; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG EFFECT; DYSPEPSIA; ERADICATION THERAPY; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NAUSEA; NONHUMAN; PEPTIC ULCER; REVIEW; SIDE EFFECT; STOMACH ADENOCARCINOMA; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037367333     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-5.
2. Anonymous. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997;41:8-13.
3. NIH Consensus Development Panel. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
4. Anonymous. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology 1997;113(Suppl):S4-8.
5. Hunt RH, Thomson ABR, Consensus Conference Participants. Canadian Helicobacter pylori Consensus Conference. Can J Gastroenterol 1998;12:31-41.
6. Hunt RH, Fallone CA, Thomson ABR, Canadian Helicobacter pylori Study Group. Canadian Helicobacter pylori Consensus Conference update: infections in adults. Can J Gastroenerol 1999;13:213-7.
7. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13(1):1-12.
8. Hentschel E, Brandstatter G, Dragosics B, Hirschl AM, Nemec H, Schutze M et al. Effects of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993;328(5):308-12.
9. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ, Saeed ZA et al. Effects of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992;116(9):705-8.
10. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991;324:1043-8.
11. Lahaie RG, Lahaie M-A, Boivin M, Gagnon M, Lemoyne M, Nguyen B et al. Changing prevalence of H. pylori infection in endoscopically demonstrated duodenal ulcer. Gastroenterology 2000;118(4):A724(3939).
12. Thiede C, Wündisch T, Alpen B, Neubauer B, Morgner A, Schmitz M et al. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 2001;19(6):1600-9.
13. Chiba N, Velduyzen van Zanten SJO, Sinclair P, Ferguson RA, Escoledo S, The CADET-Hp Study Group. Beneficial effect of H. pylori eradication therapy on long-term symptom relief in primary care patients with uninvestigated dyspepsia: the CADET-Hp Study. Gastroenterology 2000;118(4):A438(2390).
14. Heaney A, Collins JS, Watson RG, McFarland RJ, Bamford KB, Tham TC. A prospective randomized trial of "test and treat" policy versus encloscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999;45(2):186-90.
15. Moayyedi P. What is the optimum strategy for managing dyspepsia? J Gastroenterol 1998;(33 Suppl)10:44-7.
16. Makris N, Barkun AN, Fallone CA, Crott R and the UBTAN group. What is the most cost-effective strategy when managing young dyspeptic patients in the primary care setting? Gastroenterology 1999;116:A120.
17. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995;123(4):260-8.
18. Thomson ABR, Armstrong D, Barkun ANG, Chiba N, Veldhuyzen van Zanten SJO, Daniels S et al. Is prompt endoscopy necessary in uninvestigated dyspeptics? Prevalence of upper gastrointestinal abnormalities-the CADET-PE study. Gastroenterology 2001;120:A50.
19. Armstrong D, Hunt RH. Helicobacter pylori and dyspepsia: a conceptual approach. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: basic mechanisms to a clinical cure 1996. Boston: Kluwer Academic Publishers, 1996:324-39.
20. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M et al. Systemic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ 2000;321:659-64.
21. Malfertheiner P, Fischbach W, Layer P, Moessner J, Stolte M, Leodolter A et al. ELAN study proves symptomatic benefit of Helicobacter pylori eradication in functional dyspepsia (FD). Gastroenterology 2000;118(4):A2421.
22. Bruley des Varannes S, Flojou J-F, Colin R, Zam M, Meunier A. Helicobacter pylori (HP) eradication in nonulcer dyspepsia (NUD): a randomized double-blind, placebo-controlled study with a 12-month follow-up. Gastroenterology 2000;118(4):A2545.
23. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacterpylori in patients with non ulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;134(5);361-9.
24. McColl K, Murray L, El-Omar E, Dickson A. El-Nujumi A, Wirz A et al. Symptomatic benefits from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869-74.
25. Blum AL, Talley NJ, O'Morain C, van Zanten SV, Labenz J, Stolte M et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin. Effect 1 year after treatment (OCAY) Study Group. N Engl J Med 1998;339:1875-81.
26. Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E. Eradication of Helicobacter pylori in functional dyspepsia: randomized double blind placebo controlled trial with 12-month follow-up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ 1999;318:833-7.
27. Talley NJ, Vakil N, Ballard ED 2nd, Fennerty MB. Absence of benefit of eradicating Helicobacterpylori in patients with nonulcer dyspepsia. N Engl J Med 1999;341:1106-11.
28. International Agency of Research of Cancer Monographs on Evaluation for Carcinogenic Risks to Humans. Infection with Helicobacter pylori. Lyon (France): The Agency, 1994;61:177-240.
29. Anonymous. An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST study group. Lancet 1993;341(8857):1359-62.
30. Parsonnet J, Harris RA, Hack HM, Owen DK. Modeling cost effectiveness of H. pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996;348:150-4.
31. Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT et al. Atrophy and intestinal metaplasia 1 year after cure of H. pylori infection: a prospective, randomized trial. Gastroenterology 2000;119:7-14.
32. Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y et al. Improvement in atrophic gastritis and intestinal metaplasia in patients whom Helicobacter pylori was eradicated. Ann Intern Med 2001;134(5):380-6.
33. Genta RM, Franceschi F. Gastric markers of pre-malignancy are not reversible. In: Hunt RH, Tytgat GNT, editors. Helicobacter pylori: basic mechanisms to a clinical cure 2000. Boston: Kluwer Academic Publishers; 2000:525-34.
34. Uemura N, Okamoto S, Yamamoto S, Matshumura N, Yamaguchi S, Yamakido M et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345(11):784-9.
35. Forman D. Lessons from ongoing intervention studies. In: Hunt RH, Tytgat GNJ, editors. Basic mechanisms to clinical cure 1998. Boston: Kluwer Academic Publishers, 1998:354-61.
36. Fallone CA, Barkun AN, Halwani F. Does Helicobacter pylori eradication prevent gastric cancer? Dig Liver Dis 2002;1:33:803-4.
37. Werdmuller BF, Loffeld RJ. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997;42(1):103-5.
38. Fallone CA, Barkun AN, Göttke MU, Best LM, Loo VG, van Zanten SV et al. Association of Helicobacterpylori genotype with gastroesophageal reflux disease and other upper gastrointestinal diseases. Am J Gastroenterol 2000;95(3):659-69.
39. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112(5):1442-7.
40. Fallone CA, Barkun AN, Friedman G, Mayrand S, Loo V, Beech R et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000;95(4):914-20.
41. McColl KE, Dikson A, El-Nujumi A, El-Omar E, Kelman A. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:101-5.
42. Schwizer W, Thumshim, M, Dent J, Guldenschuh I, Menne D, Cathomas G et al. Helicobacter pylori and systematic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001;357:1738-42.
43. Moayyedi P, Bardhan C, Young L, Dixon M, Brown L, Axon A. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-6.
44. Kuipers E, Lundell L, Klinkenberg-Knol E, Harvu N, Festen H, Liedman B et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334(16):1018-22.
45. Lundell L, Miettinen P, Myrvold H, Pedersen S, Thor K, Andersson A et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999;117:319-26.
46. Lazzaroni M, Bianchi-Porro G. Nonsteroidal anti-inflammatory drug gastropathy and Helicobacterpylori: the search for an improbable consensus. Am J Med 2001;110(1A):50S-4.
47. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 1998;352:1016-21.
48. McColl KE, El-Omar E, Gillen D. Interactions between H. pylori infection, gastric acid secretions and antisecretory therapy. Br Medl Bull 1998;54(1):121-38.
49. Chan FKL, Sung JJY, Suen R, Lee YT, Wu JCY, Leung WK et al. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated with bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther 1998;12:1201-5.
50. Chan FKL, Sung JJY, Chung SCS, To KF, Yung MY, Leung VKS et al. Randomised trial of eradication of Helicobacter pylori Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcer. Lancet 1997;350:975-9.
51. Chan FKL, Chung SCS, Suen BY, Le YT, Leung WK, Leung VKS et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73.
52. Gunn M, Stephens JC, Thompson JR, Rathbone BJ, Samani NJ. Significant association of cag A positive Helicobacter pylori stains with risk of premature myocardial infarction. Heart 2000;84(3):267-71.
53. Di Campli C, Gasbarrini A, Nuccera E, Franceschi F, Ojetti V, Sanz Torre E et al. Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci 1998;43(6):1226-9.
54. Nishimura M, Miyajima S, Okada N. Salivary gland MALT lymphoma associated with Helicobacter pylori infection in a patients with Sjogren's Syndrome. J Dermatol 2000;27(7):450-2.
55. Ierardi E, Amoruso A, La Notte T, Francavilla R, Castellaneta S, Marrazza E et al. Halatosis and Helicobacter pylori: a possible relationship. Dig Dis Sci 1998;43(12):2733-7.
56. Gasbarrini A, Franceschi F, Gasbarrini G, Pola P. Extraintestinal pathology associated with Helicobacter infection. Eur J Gastroenterol Hepatol 1997:9(3):231-3.
57. Fox JG, Dehirst FE, Shen Z, Feng Y, Taylor NS, Paster BJ et al. Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology 1998;114:755-63.
58. Nilsson HO, Taneera J, Castedal M, Glatz E, Olsson R, Wadstrom T et al. Identification of Helicobacter pylori and Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. J Clin Microbiol 2000;38:1072-6.
59. Tran S, Fallone CA, Semret M, Behr M, Barkun AN. Helicobacter species in bile: detection and correlation with hepatobiliary disease. Gut 2001;49(Suppl 1):A69.
60. Saunders KE, Shen Z, Qewhirst FE, Paster BJ, Dangler CA, Fox JG et al. Novel intestinal Helicobacter species isolated from cotton-top tamarins (Saguinus oedipus) with chronic colitis. J Clin Microbiol 1999;37:146-51.
61. Sherman P, Hassal E, Hunt RH, Fallone CA, van Zanten VS, Thomson ABR. Canadian Helicobacter Study Group Canadian Helicobacter Study Group consensus conference on the approach to Helicobacter pylori infection in children and adolescents. Can J Gastroenterol 1999;13:553-9.
62. Drumm B, Koletzko S, Oderda G on behalf of the European Paediatric Task Force on Helicobacter pylori. Helicobacter pylori infection in children: a consensus statement. J Pediatr Gastroenterol Nutr 2000;30:207-13.
63. Gold BD, Coletti RB, Abott M, Czinn SJ, Elitsur Y, Hassall E et al. Helicobacter pylori infection in children: recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr 2000;31:490-7.
64. Graham DY, Lew GW, Malaty HM, Evans DG, Evans DJ, Klein PD et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992:102(2):493-6.
65. Fallone CA, Loo VG, Joseph L, Barkun J, Kostyk R, Barkun AN. Predictors of failure of Helicobacter pylori eradication and predictors of ulcer recurrence: a randomized controlled trial. Clin Invest Med 1999;22:185-94.
66. Cutler AF, Schubert TY. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993;88(4):505-9.
67. Brenner H, Rothenbacher D, Bode G, Adler G. Relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection: cross sectional study. BMJ 1997;315:1489-92.
68. Bardham KD, Graham Dy, Hunt RH, O'Morain CA. Effects of smoking on cure of Helicobacter pylori and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. Helicobacter 1997;2(1):27-31.
69. Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol 1994;29(12):1070-5.
70. Moayyedi P, Chalmers DM, Axon ATR. Patient factors that predict failure of omeprazole, clarithromycin, and tindazole to eradicate Helicobacter pylori. J Gastroenterol 1997;32:24-7.
71. Pipkin GA, Williamson R, Wood JR. Review article: 1-week clarithromycin triple therapy regimens for eradication of Helicobacterpylori. Aliment Pharmacol Ther 1999;12(9):823-37.
72. Chiba N, Hunt RH, Thomson AB. Ranitidine bismuth citrate. Can J Gastroenterol 2001;15(6):389-98.
73. de Boer WA, Driessen WM, Jansz AR, Tytgat GN. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in patients: results of a randomized prospective single-centre study. Eur J Gastroenterol Hepatol 1995;7(12):1189-94.
74. Lahaie R, Farley A, Dallaire C, Archambault A, Fallone CA, Ponich T et al. Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori. Can J Gastroenterol 2001;15:581-5.
75. Fallone CA. Bismuth triple and quadruple therapies in Canada. In: Hunt RH, Tygat GNT, editors. Helicobacterpylori: basic mechanisms to clinical cure 2000. Boston: Kluwer Academic Publishers, 2000:567-73.
76. Kearney DJ. Re-treatment of Helicobacter pylori infection after initial treatment failure. Am J Gastroenteol 2001;96(5):1335-9.
77. Laine LL, Hunt R, Spenard J and 54 participating investigators. Bismuth based Helicobacter pylori (Hp) therapy by a single capsule (Bismuth Subcitrate (B) + Metronidazole (M) + Tetracycline (T) + Omeprazole (O) vs (O) + Amoxicillin (A), Clarithromycin (C): an interim analysis. Gut 2000;47:A1000.
78. de Boer WA, van De Wouw BA, Schneeberger PM, Van Oijen AH, Jansen JB. Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole. Aliment Pharmacol Ther 2000;14(1):85-9.
79. Spenard A, O'Morain C, Buckley M, Borody T, Wettstein A, Farley A et al. International trial of a single-triple capsule of Bi subcitrate (B), metronidazoe (M), and tetracycline (T), given with omeprazole (O) in H. pylori (Hp) eradication: Preliminary results. Gut 2001; 49(Suppl III):A1978.